Shan Xin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shan Xin has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Sidi Chen
Department of Genetics, Yale University School of Medicine, New haven, CT, USA
11 shared publications - Guangchuan Wang
Chinese Academy of Sciences Center for Excellence in Molecular Cell Science
9 shared publications - Rong Fan
Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA
8 shared publications - Ryan Dz-Wei Chow
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
8 shared publications - Liqun Zhou
Department of Genetics, Yale University School of Medicine, New Haven, USA
6 shared publications - Chuanpeng Dong
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
5 shared publications
Latest Publications
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Spatiotemporal mapping of tertiary lymphoid structure heterogeneity shapes immune niches and clinical outcomes in intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy with limited therapeutic options. The spatial architecture and functional diversity of tertiary lymphoid structures (TLSs) in iCCA remain unclear. Here, we present a multimodal spatial atlas of TLSs and identified intratumoral TLSs (iTLSs) as independent prognostic markers. Bulk proteomic profiling of 214 discovery and 155 validation cases identified a four-tier TLS-based tumor microenvironment classification system and supported development of a TLS-predictive random forest classifier. Imaging mass cytometry revealed that iTLS + tumors harbor structured immune architectures, where M1-like tissue-resident macrophages (RTMs), dendritic cells, and CXCL13 + CD4 + T cells colocalize to form antigen-presenting neighborhoods (apc-CNs) spatially coupled to TLS core regions (TLScore-CNs). Single-cell spatial transcriptomics further resolved 61 TLSs into 14 spatial niches and defined a pseudotemporal maturation continuum: aggregated, activated, and postactivated. Intraniche communication, primarily mediated by ifnCAFs, iCAFs, and CXCL12 + macrophages, evolved dynamically with maturation. Single-nucleus RNA sequencing combined with Tangram-based spatial mapping revealed CXCL12 + macrophages and iCAFs forming a peripheral band in aggregated TLSs, whereas ifnCAFs infiltrated TLS interiors during activation. These findings define TLS heterogeneity and provide insights for stroma-directed immunotherapy.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Spatiotemporal mapping of tertiary lymphoid structure heterogeneity shapes immune niches and clinical outcomes in intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy with limited therapeutic options. The spatial architecture and functional diversity of tertiary lymphoid structures (TLSs) in iCCA remain unclear. Here, we present a multimodal spatial atlas of TLSs and identified intratumoral TLSs (iTLSs) as independent prognostic markers. Bulk proteomic profiling of 214 discovery and 155 validation cases identified a four-tier TLS-based tumor microenvironment classification system and supported development of a TLS-predictive random forest classifier. Imaging mass cytometry revealed that iTLS + tumors harbor structured immune architectures, where M1-like tissue-resident macrophages (RTMs), dendritic cells, and CXCL13 + CD4 + T cells colocalize to form antigen-presenting neighborhoods (apc-CNs) spatially coupled to TLS core regions (TLScore-CNs). Single-cell spatial transcriptomics further resolved 61 TLSs into 14 spatial niches and defined a pseudotemporal maturation continuum: aggregated, activated, and postactivated. Intraniche communication, primarily mediated by ifnCAFs, iCAFs, and CXCL12 + macrophages, evolved dynamically with maturation. Single-nucleus RNA sequencing combined with Tangram-based spatial mapping revealed CXCL12 + macrophages and iCAFs forming a peripheral band in aggregated TLSs, whereas ifnCAFs infiltrated TLS interiors during activation. These findings define TLS heterogeneity and provide insights for stroma-directed immunotherapy.
- Top Cited PapersOpen Access
- 11 June 2026
- Published by Springer Nature in Nature Biotechnology
Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT
Spatially resolved CRISPR screening in vivo has been limited to small perturbation panels and subsets of protein-coding RNAs. We present Perturb-DBiT, a method for co-sequencing of spatial total RNA whole transcriptomes and single guide RNAs (sgRNAs) on the same tissue section in situ. In a human cancer metastatic colonization model, we applied large (80,000+) sgRNA panels across tumor colonies in multiple consecutive tissue sections alongside their corresponding total RNA transcriptomes. We linked perturbations affecting long noncoding RNA covariation, microRNA–mRNA interactions and distinct amino acid-specific tRNA alterations to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further observed the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, investigation of the tumor immune microenvironment indicated distinct, synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of perturbation responses in complex tissues, including small and large RNA regulation, tumor proliferation, migration, metastasis and immune interactions.
- 11 June 2026
- Published by Springer Nature in Nature Biotechnology
Top Cited PapersOpen AccessLarge-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT
Spatially resolved CRISPR screening in vivo has been limited to small perturbation panels and subsets of protein-coding RNAs. We present Perturb-DBiT, a method for co-sequencing of spatial total RNA whole transcriptomes and single guide RNAs (sgRNAs) on the same tissue section in situ. In a human cancer metastatic colonization model, we applied large (80,000+) sgRNA panels across tumor colonies in multiple consecutive tissue sections alongside their corresponding total RNA transcriptomes. We linked perturbations affecting long noncoding RNA covariation, microRNA–mRNA interactions and distinct amino acid-specific tRNA alterations to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further observed the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, investigation of the tumor immune microenvironment indicated distinct, synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of perturbation responses in complex tissues, including small and large RNA regulation, tumor proliferation, migration, metastasis and immune interactions.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S21 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors.Significance:By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Next-generation sequencing datasets, including CRISPR screens, bulk RNA-seq, single-cell RNA-seq, and datasets related to adoptive cell therapy (ACT) and immune checkpoint blockade (ICB).
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
Source data and statistical analyses for in vivo and in vitro experiments.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- 27 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (6) , 1222-1244
Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators
The hostile tumor microenvironment (TME) remains a major challenge for cancer immunotherapy. In this study, we performed TME-targeted in vivo CRISPR activation (CRISPRa) screen to identify factors that promote antitumor immunity, culminating in rationally designed immune gene therapy combinations. Multiplexed activation of genes encoding antigen presentation, T-cell proliferation, costimulation, and migration (APCM) leads to enhanced antitumor responses. An APCM-focused CRISPRa screen in metastatic tumors identified Cd80, Tnfsf14, Cxcl10, Tnfsf18, Tnfsf9, and Ifng as top immunostimulatory candidates. Further optimization pinpointed Tnfsf9 (4-1BBL) + Ifng + Il12b (4II) as a potent therapeutic combination. Adeno-associated virus (AAV) 4II enhanced antigen presentation, T-cell activation, proliferation, cytotoxicity, and tumor infiltration. Preconditioning the TME with AAV-4II synergized with chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies to suppress primary and metastatic solid tumors in vivo. These findings establish TME-targeted CRISPRa screening as a rapid route to develop immune gene therapy combinations against solid tumors. Significance: By leveraging TME-focused in vivo CRISPRa screening, we identified immunomodulatory genes for rational AAV-based combinations that boost antitumor immunity. The optimized three-gene cocktail (4II) enhances antigen presentation and T-cell function and synergizes with adoptive T-cell therapies to improve immunotherapy efficacy in solid tumors and metastases.
- Open Access
- 1 July 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-21
Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Colorectal cancer (CRC), including both microsatellite instability (MSI) and microsatellite stability (MSS) subtypes, frequently exhibits intrinsic resistance to immunotherapy. However, the spatial tumor microenvironment (TME) and its role in distinguishing immunotherapy responders from non-responders remain poorly understood. In this study, spatial multiomics, including imaging mass cytometry (n = 50 in-house), spatial proteomics (n = 50 in-house), and spatial transcriptomics (n = 9 in-house), were employed to elucidate the spatial TME of metastatic CRC (mCRC) patients receiving immunotherapy. These methodologies were integrated with single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and bulk proteomics for comprehensive analysis and validation. A spatial immune atlas containing 314,774 cells was constructed. We found that C1QC+ resident tissue macrophages (RTMs) were more abundant in responders regardless of microsatellite status. Co-localization of C1QC+ RTMs with CD4+ T cells was observed in responders, and MHC-II expression facilitated their interaction. In contrast, cancer-associated fibroblasts inhibited this interaction in non-responders. Moreover, whole genome screening identified key genes involved in antigen presentation in C1QC+ RTMs. Hence, our study highlights the importance of spatial immune mapping in revealing the complex spatial topology of CRC and corresponding immunotherapy response.
- 1 July 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-21
Open AccessSpatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Colorectal cancer (CRC), including both microsatellite instability (MSI) and microsatellite stability (MSS) subtypes, frequently exhibits intrinsic resistance to immunotherapy. However, the spatial tumor microenvironment (TME) and its role in distinguishing immunotherapy responders from non-responders remain poorly understood. In this study, spatial multiomics, including imaging mass cytometry (n = 50 in-house), spatial proteomics (n = 50 in-house), and spatial transcriptomics (n = 9 in-house), were employed to elucidate the spatial TME of metastatic CRC (mCRC) patients receiving immunotherapy. These methodologies were integrated with single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, and bulk proteomics for comprehensive analysis and validation. A spatial immune atlas containing 314,774 cells was constructed. We found that C1QC+ resident tissue macrophages (RTMs) were more abundant in responders regardless of microsatellite status. Co-localization of C1QC+ RTMs with CD4+ T cells was observed in responders, and MHC-II expression facilitated their interaction. In contrast, cancer-associated fibroblasts inhibited this interaction in non-responders. Moreover, whole genome screening identified key genes involved in antigen presentation in C1QC+ RTMs. Hence, our study highlights the importance of spatial immune mapping in revealing the complex spatial topology of CRC and corresponding immunotherapy response.
- Top Cited PapersOpen Access
- 8 May 2025
- Published by Springer Nature in Research Square
Spatially Resolved Panoramic in vivo CRISPR Screen via Perturb-DBiT
Spatially resolved in vivo CRISPR screening integrates gene editing with spatial transcriptomics to examine how genetic perturbations alter gene expression within native tissue environments. However, current methods are limited to small perturbation panels and the detection of a narrow subset of protein-coding RNAs. We present Perturb-DBiT, a distinct and versatile approach for the simultaneous co-sequencing of spatial total RNA whole-transcriptome and single-guide RNAs (sgRNAs), base-by-base, on the same tissue section. This method enables unbiased discovery of how genetic perturbations influence RNA regulation, cellular dynamics, and tissue architecture in situ. Applying Perturb-DBiT to a human cancer metastatic colonization model, we mapped large panels of sgRNAs across tumor colonies in consecutive tissue sections alongside their corresponding total RNA transcriptomes. This revealed novel insights into how perturbations affect long non-coding RNA (lncRNA) co-variation, microRNA–mRNA interactions, and global and distinct tRNA alterations in amino acid metabolism linked to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further uncovered the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, Perturb-DBiT enabled investigation of genetic perturbations within the tumor immune microenvironment, revealing distinct and synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of how genetic knockouts influence diverse molecular and cellular responses including small and large RNA regulation, tumor proliferation, migration, metastasis, and immune interactions, offering a panoramic perspective on perturbation responses in complex tissues.
- 8 May 2025
- Published by Springer Nature in Research Square
Top Cited PapersOpen AccessSpatially Resolved Panoramic in vivo CRISPR Screen via Perturb-DBiT
Spatially resolved in vivo CRISPR screening integrates gene editing with spatial transcriptomics to examine how genetic perturbations alter gene expression within native tissue environments. However, current methods are limited to small perturbation panels and the detection of a narrow subset of protein-coding RNAs. We present Perturb-DBiT, a distinct and versatile approach for the simultaneous co-sequencing of spatial total RNA whole-transcriptome and single-guide RNAs (sgRNAs), base-by-base, on the same tissue section. This method enables unbiased discovery of how genetic perturbations influence RNA regulation, cellular dynamics, and tissue architecture in situ. Applying Perturb-DBiT to a human cancer metastatic colonization model, we mapped large panels of sgRNAs across tumor colonies in consecutive tissue sections alongside their corresponding total RNA transcriptomes. This revealed novel insights into how perturbations affect long non-coding RNA (lncRNA) co-variation, microRNA–mRNA interactions, and global and distinct tRNA alterations in amino acid metabolism linked to tumor migration and growth. By integrating transcriptional pseudotime trajectories, we further uncovered the impact of perturbations on clonal dynamics and cooperation. In an immune-competent syngeneic mouse model, Perturb-DBiT enabled investigation of genetic perturbations within the tumor immune microenvironment, revealing distinct and synergistic effects on immune infiltration and suppression. Perturb-DBiT provides a spatially resolved comprehensive view of how genetic knockouts influence diverse molecular and cellular responses including small and large RNA regulation, tumor proliferation, migration, metastasis, and immune interactions, offering a panoramic perspective on perturbation responses in complex tissues.
- 15 April 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (27) , 2268-2282
Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis
Primary breast cancer (BC) and metastatic tumors exhibit distinct tumor microenvironment (TME) ecosystems, and the heterogeneity of the TME of BC poses challenges to effective therapies. Evaluating the TME at the single-cell and spatial profiles offers potential for more precise treatments. However, due to the challenge of obtaining surgical specimens of both primary BC and oligo-recurrent lung metastasis simultaneously for high-resolution spatial analysis, the TME of lung-specific metastases using paired samples remains largely unexplored. In this study, we developed a comprehensive strategy using imaging mass cytometry (IMC), spatial proteomics, single-nucleus RNA-seq (snRNA-seq) and multiplex immunofluorescence to explore the spatial topology of lung-specific metastasis and the underlying biological mechanisms based on formalin-fixed paraffin-embedded (FFPE) samples from BC and paired lung metastasis. A total of 250,600 high-quality cells with spatial information revealed by IMC depicted the spatial differences in the TME between BC and lung metastasis. A significant increase in HLA-DR+ epithelial cells, endothelial cells and exhausted T cells was detected in lung metastases compared to primary sites, with this difference accentuated in the triple-negative subtype. Moreover, a distinct cellular hub comprising endothelial cells and HLA-DR+ epithelial cells implies the potential promising effect of anti-angiogenic therapy and immunotherapy in BC with lung metastasis, which was further validated by multiplex immunofluorescence analysis. Spatial proteomics further explored the underlying mechanism of TME components identified by IMC analysis. snRNA-seq validated the enrichment of endothelial cells in lung metastasis than that in BC at a whole FFPE slide level. In conclusion, this study determines the spatial multi-omics profiling of TME components at a single-cell resolution using paired samples of primary BC and lung oligo-metastasis. The comprehensive analysis may contribute to the development of therapeutic options.
- 15 April 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (27) , 2268-2282
Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis
Primary breast cancer (BC) and metastatic tumors exhibit distinct tumor microenvironment (TME) ecosystems, and the heterogeneity of the TME of BC poses challenges to effective therapies. Evaluating the TME at the single-cell and spatial profiles offers potential for more precise treatments. However, due to the challenge of obtaining surgical specimens of both primary BC and oligo-recurrent lung metastasis simultaneously for high-resolution spatial analysis, the TME of lung-specific metastases using paired samples remains largely unexplored. In this study, we developed a comprehensive strategy using imaging mass cytometry (IMC), spatial proteomics, single-nucleus RNA-seq (snRNA-seq) and multiplex immunofluorescence to explore the spatial topology of lung-specific metastasis and the underlying biological mechanisms based on formalin-fixed paraffin-embedded (FFPE) samples from BC and paired lung metastasis. A total of 250,600 high-quality cells with spatial information revealed by IMC depicted the spatial differences in the TME between BC and lung metastasis. A significant increase in HLA-DR+ epithelial cells, endothelial cells and exhausted T cells was detected in lung metastases compared to primary sites, with this difference accentuated in the triple-negative subtype. Moreover, a distinct cellular hub comprising endothelial cells and HLA-DR+ epithelial cells implies the potential promising effect of anti-angiogenic therapy and immunotherapy in BC with lung metastasis, which was further validated by multiplex immunofluorescence analysis. Spatial proteomics further explored the underlying mechanism of TME components identified by IMC analysis. snRNA-seq validated the enrichment of endothelial cells in lung metastasis than that in BC at a whole FFPE slide level. In conclusion, this study determines the spatial multi-omics profiling of TME components at a single-cell resolution using paired samples of primary BC and lung oligo-metastasis. The comprehensive analysis may contribute to the development of therapeutic options.